Federal medical-device recall records identify the U.S. Virgin Islands among distribution areas for intravenous tubing manufactured by ICU Medical after reports of black specks and discoloration in the products' drip chambers. The Food and Drug Administration has classified the action as a Class II recall, although the manufacturer says its investigation found no direct patient risk and that the devices can continue to be used.
The affected products include IV administration sets used to deliver fluids and medications to patients, as well as specialized sets used in cancer treatment. FDA records list the Virgin Islands among the domestic and international markets where the products were distributed, but do not identify the healthcare facilities that received them or how many units were shipped to the territory.
The recall was initiated by ICU Medical on May 12, 2026, and entered into the FDA's recall database on September 11. On October 5, the agency updated its public safety communication to reflect the manufacturer's completed investigation and the classification of the action as a Class II recall.
According to the FDA, the issue emerged after ICU Medical received reports of small black specks and discoloration on the inner walls of drip chambers, along with reports of particulate matter inside some chambers. The initial concern was whether the material represented contamination or could enter the fluid pathway through which intravenous medications and other solutions are delivered to patients.
The manufacturer subsequently examined returned products, performed laboratory analysis and simulated-use testing, and inspected its inventory. ICU Medical determined that the reported discoloration was embedded within the polyvinyl chloride, or PVC, used to manufacture the drip chambers.
According to the company's investigation, the discoloration was not biological contamination or foreign material, did not enter the fluid pathway, and did not dislodge under expected conditions of use. The company also found no adverse effect on the chambers' structural integrity or performance.
The FDA's updated notice reflects those findings while continuing to classify the corrective action as a Class II recall. Under that classification, a product may cause temporary or medically reversible adverse health consequences, or the probability of serious adverse health consequences is considered remote.
Treatment Delays Identified as Potential Risk
Although the investigation found no direct patient risk associated with using the affected products, the manufacturer identified a potential concern involving interruptions to medical treatment.
A healthcare provider who notices dark discoloration in an IV drip chamber could decide to replace the device before administering treatment. The resulting delay could be clinically significant when a patient requires a time-sensitive infusion or when a replacement device is not readily available.
The FDA's notice states that ICU Medical had not reported any serious injuries or deaths associated with the issue as of July 16, 2026.
In a July 28 corrective notice, the company instructed healthcare facilities to continue using the affected products according to their intended use and established clinical procedures. No product returns were required, and the manufacturer withdrew an earlier recommendation for enhanced inspections after its investigation determined that the discoloration did not compromise device safety or performance.
Healthcare providers were nevertheless advised to follow normal inspection procedures before use. If loose particulate matter is observed in the fluid pathway, the individual device should be separated from other supplies, and ICU Medical should be contacted for further investigation.
Virgin Islands Listed in Distribution Records
The FDA's recall database contains eight related records covering several categories of ICU Medical tubing, including Plum administration sets, non-dedicated gravity administration sets, oncology sets and other intravenous administration products.
The manufacturer's July 28 notice covers affected products manufactured on or before July 4, 2026, that remain within their expiration dates.
One FDA recall entry lists approximately 100.7 million IV administration units in commerce worldwide. That figure relates to one product category and does not represent the number distributed to the Virgin Islands or the number of devices removed from use.
The federal distribution records explicitly include the Virgin Islands, along with Puerto Rico, Guam, numerous states and several foreign countries.
However, the publicly available records do not specify whether the Juan F. Luis Hospital on St. Croix, Schneider Regional Medical Center on St. Thomas, or other territorial healthcare providers purchased or received the affected products. They also do not establish whether any devices showing discoloration were identified locally.
The extent of the products' distribution within the territory, including the number of units potentially held by local healthcare facilities, remains unconfirmed.
The FDA continues to list the related recall actions as open. ICU Medical has instructed customers to share its corrective notice with all users of the affected devices, acknowledge receipt of the communication and report any product-quality concerns to the manufacturer.
